Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.

STRIDE-III updates IBD treatment targets, defining 13,071 records and establishing three categories of targets to guide treat-to-target care.

• Why it matters: Effective management of inflammatory bowel disease requires clear, evidence-based targets to improve patient outcomes and optimize treatment strategies, addressing gaps in previous guidelines.
• What they did: The study integrated systematic review, surveys of gastroenterologists, and Delphi consensus to categorize targets into actionable, adjunctive, and patient-centered, with specific timing and thresholds.
• The result: This framework enables clinicians to distinguish targets prompting treatment change from those for monitoring, supporting consistent, patient-centered, and evidence-based IBD care.